BX Home
Cancer
Advanced U.S. Clinical Trial Confirms Single-Agent Efficacy of...

Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more

Register using your

account Register for Beta

CANCER back to topic

Advanced U.S. Clinical Trial Confirms Single-Agent Efficacy of Rexin-G in Metastatic Pancreas Cancer: All Endpoints Achieved - Drugs and Pharmaceuticals News

Epeius Biotechnologies Reports Dose-Dependent Efficacy and Survival Benefits. SAN MARINO, Calif., Oct. 14 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies (www.epeiusbiotech.com) confirms the first real breakthrough for pancreatic cancer seen in...

send2press.com. Added by Christopher Simmons on October 14, 2009

Read the full Article

report

save

This article has:

1 view
1 save

Reactions to Advanced U.S. Clinical Trial Confirms Single-Agent Efficacy of Rexin-G in Metastatic Pancreas Cancer: All Endpoints Achieved - Drugs and Pharmaceuticals News

Christopher Simmons saved this article 41 days ago

Date

Type Channel Author

Search Cancel

McGraw-Hill Education Standard & Poors BusinessWeek Platts McGraw-Hill Construction AviationWeek McGraw-Hill Broadcasting J.D. Power

Advanced U.S. Clinical Trial Confirms Single-Agent Efficacy of Rexin-G in Metastatic Pancreas Cancer: All Endpoints Achieved - Drugs and Pharmaceuticals News

Reactions to Advanced U.S. Clinical Trial Confirms Single-Agent Efficacy of Rexin-G in Metastatic Pancreas Cancer: All Endpoints Achieved - Drugs and Pharmaceuticals News

Join Business Exchange

Member sign in

ALSO IN THIS TOPIC Cancer